These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 1900222

  • 1. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 2. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
    Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR.
    J Am Coll Cardiol; 1993 Jul; 22(1):296-301. PubMed ID: 8509554
    [Abstract] [Full Text] [Related]

  • 3. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 4. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 5. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE, Abendschein DR.
    Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
    [Abstract] [Full Text] [Related]

  • 11. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH.
    Circulation; 1996 Feb 15; 93(4):792-9. PubMed ID: 8641009
    [Abstract] [Full Text] [Related]

  • 12. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL.
    J Am Coll Cardiol; 1994 Apr 15; 23(5):993-1003. PubMed ID: 8144799
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 15; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 16. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun 15; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 17. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb 15; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 18. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
    Uriuda Y, Wang QD, Hatori N, Nordlander R, Sjöquist PO, Mattsson C, Rydén L.
    J Pharmacol Toxicol Methods; 1998 Mar 15; 39(2):81-9. PubMed ID: 9694166
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
    Fitzgerald DJ, Hanson M, FitzGerald GA.
    J Clin Invest; 1991 Nov 15; 88(5):1589-95. PubMed ID: 1939647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.